Leah Cooksey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leah Cooksey has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Barbara-Ann Guinn
Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK
2 shared publications - Daniel M. Fletcher
Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK
2 shared publications - Eithar Mohamed
Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK
2 shared publications - Kenneth I. Mills
Queens University Belfast, Belfast, United Kingdom
2 shared publications - Kim Orchard
Wessex Blood and Marrow Transplantation Programme, Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2 shared publications - Sara Goodman
Centre for Biomedicine, Hull York Medical School, University of Hull, Cottingham Road, Kingston-Upon-Hull HU6 7RX, UK
2 shared publications
Latest Publications
- Open Access
Adult B-Cell Acute Lymphoblastic Leukaemia Antigens and Enriched Pathways Identify New Targets for Therapy
Background: Adult B-cell acute lymphoblastic leukaemia (aB-ALL) is characterised by abnormal differentiation and proliferation of lymphoid progenitors. Despite a significant improvement in relapse-free and overall survival for children with B-ALL, aB-ALL has a particularly poor prognosis with a 5-year survival rate of 20%. First remission is achieved for most patients, but relapse is common with a high associated mortality. New treatments such as immunotherapy offer an opportunity to extend remission and prevent relapse. Methods: aB-ALL antigens were identified using different sources—immunoscreening, protoarrays, two microarrays and one cancer-testis antigen database, and a review of the genomic analyses of aB-ALL. A total of 385 aB-ALL-associated gene products were examined for their association with patient survival. Results: We identified 87 transcripts with differential expression between aB-ALL and healthy volunteers (peripheral blood, bone marrow and purified CD19+ cells), and 42 that were associated with survival. Enrichr analysis showed that the Transforming Growth Factor-β (TGFβ), Wnt and Hippo pathways were highly represented (p < 0.02). We found that SOX4 and ROCK1 were upregulated in all types of B-ALL (ROCK1 having a p < 0.001 except in t(8;14) patients), as well as SMAD3 and TEAD4 upregulation being associated with survival (p = 0.0008, 0.05 and 0.001, respectively). Expression of each aB-ALL antigen was verified by qPCR, but only TEAD4 showed significant transcript upregulation in aB-ALL compared to healthy volunteer CD19+ cells (p = 0.01). Conclusions: We have identified a number of antigens and their pathways that play key roles in aB-ALL and may act as useful targets for future immunotherapy strategies.
Open AccessAdult B-Cell Acute Lymphoblastic Leukaemia Antigens and Enriched Pathways Identify New Targets for Therapy
Background: Adult B-cell acute lymphoblastic leukaemia (aB-ALL) is characterised by abnormal differentiation and proliferation of lymphoid progenitors. Despite a significant improvement in relapse-free and overall survival for children with B-ALL, aB-ALL has a particularly poor prognosis with a 5-year survival rate of 20%. First remission is achieved for most patients, but relapse is common with a high associated mortality. New treatments such as immunotherapy offer an opportunity to extend remission and prevent relapse. Methods: aB-ALL antigens were identified using different sources—immunoscreening, protoarrays, two microarrays and one cancer-testis antigen database, and a review of the genomic analyses of aB-ALL. A total of 385 aB-ALL-associated gene products were examined for their association with patient survival. Results: We identified 87 transcripts with differential expression between aB-ALL and healthy volunteers (peripheral blood, bone marrow and purified CD19+ cells), and 42 that were associated with survival. Enrichr analysis showed that the Transforming Growth Factor-β (TGFβ), Wnt and Hippo pathways were highly represented (p < 0.02). We found that SOX4 and ROCK1 were upregulated in all types of B-ALL (ROCK1 having a p < 0.001 except in t(8;14) patients), as well as SMAD3 and TEAD4 upregulation being associated with survival (p = 0.0008, 0.05 and 0.001, respectively). Expression of each aB-ALL antigen was verified by qPCR, but only TEAD4 showed significant transcript upregulation in aB-ALL compared to healthy volunteer CD19+ cells (p = 0.01). Conclusions: We have identified a number of antigens and their pathways that play key roles in aB-ALL and may act as useful targets for future immunotherapy strategies.
- Open Access
- 17 February 2025
- Published by MDPI AG in Preprints.org
Adult B-Cell Acute Lymphoblastic Leukaemia Antigens and Enriched Pathways Identify New Targets for Therapy
Background: Adult B-cell acute lymphoblastic leukaemia (aB-ALL) is characterised by abnormal differentiation and proliferation of lymphoid progenitors. Despite a significant improvement in relapse-free and overall survival for children with B-ALL, aB-ALL has a particularly poor prognosis with a 5-year survival rate of 20%. First remission is achieved for most patients but relapse is common with a high associated mortality. New treatments such as immunotherapy offer an opportunity to extend remission and prevent relapse. Methods: aB-ALL antigens were identified using different sources - immunoscreening, protoarrays, two microarrays and one cancer-testis antigen (CTA) database, and a review of the genomic analyses of aB-ALL. 385 aB-ALL-associated gene products were examined for their association with patient survival. Results: We identified 87 transcripts with differential expression between aB-ALL and healthy donors, and 42 that were associated with survival. Enrichr analysis showed that the Transforming Growth Factor-β (TGFβ), Wnt and hippo pathways were highly represented (p<0.02). We found that SOX4 was upregulated in all types of B-ALL, while ROCK1 was upregulated in all types of B-ALL (p<0.001 except t(8;14)) and along with SMAD3 and TEAD4 were associated with survival (p=0.0008, 0.05 and 0.001 respectively). Expression of each aB-ALL antigen was verified by qPCR but only TEAD4 showed significant transcript upregulation in aB-ALL compared to healthy donor CD19+ cells (p=0.01). Conclusions: We have identified a number of antigens and their pathways that play key roles in aB-ALL and may act as useful targets for future immunotherapy strategies.
- 17 February 2025
- Published by MDPI AG in Preprints.org
Open AccessAdult B-Cell Acute Lymphoblastic Leukaemia Antigens and Enriched Pathways Identify New Targets for Therapy
Background: Adult B-cell acute lymphoblastic leukaemia (aB-ALL) is characterised by abnormal differentiation and proliferation of lymphoid progenitors. Despite a significant improvement in relapse-free and overall survival for children with B-ALL, aB-ALL has a particularly poor prognosis with a 5-year survival rate of 20%. First remission is achieved for most patients but relapse is common with a high associated mortality. New treatments such as immunotherapy offer an opportunity to extend remission and prevent relapse. Methods: aB-ALL antigens were identified using different sources - immunoscreening, protoarrays, two microarrays and one cancer-testis antigen (CTA) database, and a review of the genomic analyses of aB-ALL. 385 aB-ALL-associated gene products were examined for their association with patient survival. Results: We identified 87 transcripts with differential expression between aB-ALL and healthy donors, and 42 that were associated with survival. Enrichr analysis showed that the Transforming Growth Factor-β (TGFβ), Wnt and hippo pathways were highly represented (p<0.02). We found that SOX4 was upregulated in all types of B-ALL, while ROCK1 was upregulated in all types of B-ALL (p<0.001 except t(8;14)) and along with SMAD3 and TEAD4 were associated with survival (p=0.0008, 0.05 and 0.001 respectively). Expression of each aB-ALL antigen was verified by qPCR but only TEAD4 showed significant transcript upregulation in aB-ALL compared to healthy donor CD19+ cells (p=0.01). Conclusions: We have identified a number of antigens and their pathways that play key roles in aB-ALL and may act as useful targets for future immunotherapy strategies.